Mission Creek Capital Partners’s 10x Genomics TXG Stock Holding History

Mission Creek Capital Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-20,000	Closed	-$3.92M	–	256
2021 Q2	$3.92M	Buy	20,000 +16,956	+557%	+$3.07M	0.63%	21
2021 Q1	$551K	Sell	3,044 -44,857	-94%	-$7.75M	0.08%	150
2020 Q4	$6.78M	Buy	47,901 +44,077	+1,153%	+$6.4M	2.08%	6
2020 Q3	$477K	Buy	+3,824	New	+$401K	0.19%	132
2020 Q2	–	Sell	-3,958	Closed	-$247K	–	177
2020 Q1	$247K	Buy	+3,958	New	+$309K	0.13%	146

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

MCAV

Meritech Capital Associates V Palo Alto, California $141M AUM 15.44% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mission Creek Capital Partners's TXG Position: Q3 2021 in Review

Mission Creek Capital Partners sold out of 10x Genomics (TXG) in Q3 2021, closing a stake of 20,000 shares — an estimated $3.92M sold.

Mission Creek Capital Partners first reported a position in TXG in Q1 2020 and held it in 5 quarters. The position peaked at $6.78M in Q4 2020. 330 funds tracked by Wall St. Rank hold TXG as of Q3 2021.

Mission Creek Capital Partners reported no remaining 10x Genomics position as of Q3 2021 after selling out during the quarter.
Mission Creek Capital Partners sold 20,000 10x Genomics shares in Q3 2021, an estimated $3.92M.
Mission Creek Capital Partners first reported a position in 10x Genomics in Q1 2020 and held it in 5 quarters.
Mission Creek Capital Partners's 10x Genomics position peaked at $6.78M in Q4 2020.
330 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2021.

Based on Mission Creek Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.